Publication
, Other
Li, R; Sexton, WJ; Dhillon, J; Berglund, A; Naidu, S; Borjas, G; Rose, K; Kim, Y; Wang, X; Conejo-Garcia, JR; Jain, RK; Poch, MA; Spiess, PE ...
September 16, 2024
APA
Chicago
ICMJE
MLA
NLM
Li, R., Sexton, W. J., Dhillon, J., Berglund, A., Naidu, S., Borjas, G., … Zhang, J. (2024). Data from A Phase 2 Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder. https://doi.org/10.1158/1078-0432.c.6861175.v2
Li, Roger, Wade J. Sexton, Jasreman Dhillon, Anders Berglund, Shreyas Naidu, Gustavo Borjas, Kyle Rose, et al. “Data from A Phase 2 Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder,” September 16, 2024. https://doi.org/10.1158/1078-0432.c.6861175.v2.
Li R, Sexton WJ, Dhillon J, Berglund A, Naidu S, Borjas G, et al. Data from A Phase 2 Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder. 2024.
Li, Roger, et al. Data from A Phase 2 Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder. 16 Sept. 2024. Crossref, doi:10.1158/1078-0432.c.6861175.v2.
Li R, Sexton WJ, Dhillon J, Berglund A, Naidu S, Borjas G, Rose K, Kim Y, Wang X, Conejo-Garcia JR, Jain RK, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Zhang J. Data from A Phase 2 Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder. 2024.